MONTREAL, QC and WILMINGTON, DE, Dec. 4 /PRNewswire-FirstCall/ - Millenia Hope Biopharma a related company to Millenia Hope Inc. announced today that it has opened a new facility in Kirkland Quebec. The new facility is located in the centre of Montreal's pharmaceutical industry and provides MHB with better access to the trained pharmaceutical staff and the additional high quality space needed to expand manufacturing. The building has 34,000 sq ft of space of which 12,000 sq ft is manufacturing clean space, 2,000 sq ft is laboratory and 10,000 sq ft is office space. This new facility substantially also lowers the operational cost of MHB compared to its previous facility in Laval.
Mr. Leonard Stella, Chairman & CEO of Millenia Hope Inc., and the parent company to Millenia Hope Biopharma said, "This is an essential part of our transformation of Millenia Hope Biopharma since it was acquired in February of this year. We have put in place a new business development strategy, which involves expanding manufacturing capacity and adding key commercial and management expertise to what was an outstanding scientific group. Our goal is have Millenia Hope Biopharma cash flow positive in early 2008. Ms. Francine Sauriol, President of Focus Biotech Consultants, has agreed to take on the crucial task of Director of Business Development."
Dr Bahige Baroudy, President and Chief Scientific Officer of Millenia Hope Inc. also made some important announcements concerning the parent company Millenia Hope Inc. Professor Pierre Sirois, of the Universite de Sherbrooke, an international expert in the fields of asthma and inflammation has joined Millenia Hope as Chief Pharmacologist. Dr. Bruno Battistini, an Adjunct Professor at the Universite de Sherbrooke and formerly Chief Scientific Officer of IPS Pharma, has joined Millenia Hope Inc. as Chief Regulatory & R&D Officer. Mr. Luc Vaugeois has joined the company as Director of Operations with responsibility for manufacturing and quality. Dr. Baroudy said "We are achieving our goal of attracting world class expertise as part of our campaign to bring affordable plant based therapeutic products to third world countries."
ABOUT MILLENIA HOPE INC & MILLENIA HOPE BIOPHARMA:
Millenia Hope develops innovative treatments and products that enhance the quality of life. The company has put in place programs to fight major infectious diseases and promote healthier lives and is committed to research and development to deliver on global medical needs and to bring hope through healthcare solutions. Founded in 1997 the company has initially focussed on the need to bring safe and affordable herbal therapies to market for major third world diseases such as malaria and HIV. The first product in this series is MMH(TM)Malarex / MMH(TM)18,. Millenia is also pursuing inhibitors of HIV RNase H (patent application pending). Successful development of a drug that targets HIV RNase H will play an important role in the treatment of HIV/AIDS patients who have become resistant to current therapy. www.milleniahope.com
Millenia Hope Biopharma (MHB) a related company to MHI, founded in 2000, is the world's leading bioresearch firm in Phytomic Technologies, commercializing plant cell-based bioprocesses for the discovery, development and production of natural and novel plant-derived products for the pharmaceutical, cosmetic and nutraceutical industries. Avance Pharma has spent over US$25 million in developing its unique proprietary Phytomics Technologies which now belongs to MHB, including the world's largest collection of highly purified phytochemical fractions to be utilized in the pharmaceutical, cosmetic and nutraceutical industry. MHB also provides a plant based drug discovery platform designed for High Throughput Screening and is currently working with a number of leading multinational corporations such as Pierre Fabre Medicaments. www.mh-b.com.
SAFE HARBOR STATEMENTS:
Certain statements made in this release may contain language describing the plans, goals, strategies, intentions, forecasts, and expectations of Holley Pharmaceuticals Company Inc. that may be referred to as "forward- looking statements." Several important factors could cause actual results to differ materially from those in such forward-looking statements and Holley Pharmaceuticals Company Inc. could encounter unanticipated obstacles and delays in developing products, services and markets.
Millenia Hope BiopharmaCONTACT: Mr Leonard Stella, CEO, Millenia Hope Inc., (514) 846-5757,leostella@milleniahope.com
